On the extrapolation from animal models to human disease for the design of immunotherapy in autoimmune diabetes
Type 1 diabetes, insulin-dependent diabetes mellitus (IDDM) is a T-cell-mediated autoimmune disease (Bach 1994). It is thus logical to attempt to stop or better prevent disease progression by immunotherapy. A multitude of immunological treatments have been shown to be successful in the most currently available model of type 1 diabetes, namely, the nonobese diabetic (NOD) mouse. This observation may be taken in a positive fashion, paving the way for testing these strategies in humans. Conversely, one may wonder whether the NOD mouse is not, in some ways, “too sensitive” to immunological intervention, rendering the extrapolation of results obtained in NOD mice to human diabetes uncertain. This is, in fact, a very complex question which shall be addressed in some detail below.
KeywordsGlutamic Acid Decarboxylase Nonobese Diabetic Mouse Antilymphocyte Serum Positive Fashion Kampo Formulation
Unable to display preview. Download preview PDF.
- Bach J-F (1994) Insulin-dependent diabetes mellitus as an autoimmune disease. Endocrine Rev 15: 516–542Google Scholar
- Bach J-F (1998) The natural history of islet-specific autoimmunity in NOD mice. In: Leiter E, Atkinson M (eds) NOD mice and related strains: research applications in diabetes, AIDS, cancer and other diseases. RG Landes, Austin, Tex, pp 121–144Google Scholar
- Feutren G, Papoz L, Assan R, Vialettes B, Karsenty G, Yexiau P, Du Rostu H, Rodier M, Sirmai J, Lallemand A, Bach J-F (1986) Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset: results of a multicentre double-blind trial. Lancet 2: 119–124PubMedCrossRefGoogle Scholar
- Kim JY, Cho SH, Kim YW, Jang EC, Park SY, Kim EJ, Lee SK (1999) Effects of BCG, lymphotoxin and bee venom on insulitis and development of IDDM in non-obese diabetic mice. J Kor Med Sci 14: 648–652Google Scholar